Entero Therapeutics Bolsters Balance Sheet and Board with Strategic Moves

Entero Therapeutics, Inc. (ENTO) has taken significant steps to strengthen its financial position and governance by securing a $2 million revolving loan agreement and appointing three new members to its Board of Directors. These moves, announced on February 7, 2025, aim to provide working capital, support operations, and enhance the company's strategic direction.

The $2 million revolving loan agreement will help Entero Therapeutics maintain its cash flow and continue investing in its targeted, non-systemic therapies for gastrointestinal (GI) diseases. The financing is expected to bridge the company to an anticipated subsequent public offering, further bolstering its financial stability. This additional funding will enable Entero Therapeutics to advance its clinical trials, conduct further research and development, and potentially bring its drug candidates to market more quickly.



The company's strategic appointment of three new Board members – Richard Paolone, Eric Corbett, and Manpreet Uppal – brings diverse expertise and leadership experience to Entero Therapeutics. Paolone, a Toronto-based securities lawyer, will contribute valuable insights in securities law and corporate governance. Corbett, a managing director with experience in capital markets and corporate finance advisory services, will provide crucial guidance in financial decision-making and capital raising efforts. Uppal, with experience in capital markets and real estate, will offer a unique perspective on strategic investments and partnerships.

These appointments follow the resignations of James Sapirstein, Alastair Riddell, and Timothy Ramdeen from the Board. The new directors' expertise in capital markets, corporate finance, and legal matters is expected to enhance Entero Therapeutics' governance and strategic direction, ultimately driving value for shareholders.

Entero Therapeutics' programs address significant unmet needs in GI health, including latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

By securing this financing and appointing new Board members, Entero Therapeutics has taken proactive steps to strengthen its financial position and governance. These moves demonstrate the company's commitment to driving value for shareholders and advancing its targeted, non-systemic therapies for GI diseases. As Entero Therapeutics continues to navigate the complex landscape of biopharmaceutical development and public offerings, investors can expect the company to maintain a strategic focus on growth and innovation.